FAQ on Scinai Immunotherapeutics' Anti-IL-17 NanoAb and PEI Feedback

What is Scinai Immunotherapeutics’ main focus?

Scinai Immunotherapeutics focuses on developing inflammation and immunology (I&I) biological products and provides contract development and manufacturing organization (CDMO) services through its Scinai Bioservices business unit.

What feedback did Scinai receive from the PEI?

The PEI provided positive regulatory feedback on Scinai’s anti-IL-17A/F nanoAb (SCN-1) for plaque psoriasis, including acceptance of preclinical toxicology studies in pigs and clinical program plans, and noted the manufacturing process is well developed.

Why is the PEI feedback significant for Scinai?

The feedback is significant as it supports Scinai’s drug-development plans for SCN-1, allowing faster development by accepting proposed preclinical and clinical strategies without the need for testing in healthy volunteers.

When does Scinai anticipate starting the preclinical trial for SCN-1?

Scinai Immunotherapeutics anticipates the preclinical trial will start in the second half of 2025.

What are the implications of the PEI’s feedback for patients with psoriasis?

The PEI acknowledged the unmet need for better therapies in mild-to-moderate psoriasis patients, supporting Scinai’s approach to directly compare SCN-1 to placebo in these patients, potentially leading to faster development of an effective treatment.

How does Scinai’s approach compare to traditional drug development methods?

Scinai’s approach is innovative by skipping testing in healthy volunteers and directly comparing SCN-1 to placebo in patients with mild to moderate plaque psoriasis, which was accepted by the PEI, potentially speeding up the development process.

Where can I find more information about Scinai Immunotherapeutics?

For more information, visit the company’s website at www.Scinai.com or view the full press release at https://ibn.fm/KInAu.

Who is leading the development of SCN-1 at Scinai Immunotherapeutics?

Dr. Tamar Ben-Yedidia, Scinai Immunotherapeutics’ chief scientist, is leading the development, as mentioned in the press release regarding the PEI’s supportive regulatory summary.